News Channels

13 Mar 2018 Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
13 Mar 2018 Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan
13 Mar 2018 Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
13 Mar 2018 Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501
13 Mar 2018 Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
13 Mar 2018 Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
13 Mar 2018 AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
13 Mar 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
13 Mar 2018 Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
13 Mar 2018 BioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation
13 Mar 2018 Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
13 Mar 2018 Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
13 Mar 2018 Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
13 Mar 2018 Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
12 Mar 2018 All time high of biologics sales in 2017 driven by cancer and innovative anti-inflammatory antibodies
12 Mar 2018 Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
12 Mar 2018 INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
12 Mar 2018 IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer
12 Mar 2018 XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
12 Mar 2018 Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing